Skip to main content

Table 1 General characteristics of randomized controlled trials

From: Systematic evaluation of the methodology of randomized controlled trials of anticoagulation in patients with cancer

 

Overall, n (%) N=67

Funding source

 

governmental

12 (18)

private not for profit

3 (4)

private for profit

41 (61)

Private for profit plus other source

4 (6)

Not funded

3 (4)

Not reported

14 (21)

Publication language

 

English

67 (100)

Sample size

 

Median (Q1-Q3)

156 (74-355)

n <200

39 (58)

n ≥200

28 (42)

Type of cancer

 

Participants with different cancer types

47 (70)

Cancer type not reported

5 (7)

All participants with same cancer type

15 (22)

Lung

5 (33)

Colorectal

2 (13)

Gynecologic

2 (13)

Prostate

1 (7)

Breast

1 (7)

Pancreatic

1 (7)

Hematological

2 (13)

Hematological and solid tumors

1 (6)

Cancer as subgroup of the study

27 (40)

Intervention

 

LMWH

53 (79)

UFH

33 (49)

Vitamin K antagonist

20 (30)

Direct thrombin inhibitors

5 (7)

Fondaparinux

3 (4)

Comparator

 

Active treatment

47 (70)

Placebo

9 (13)

No treatment

11 (17)

  1. LMWH=Low molecular weight heparin, UFH=Unfractioned Heparin, VTE=Venous thromboembolism, PE=Pulmonary embolism, DVT=Deep vein thrombosis.